| Primary |
| Product Used For Unknown Indication |
34.6% |
| Drug Use For Unknown Indication |
27.4% |
| Hyperparathyroidism Secondary |
8.1% |
| Renal Failure Chronic |
6.2% |
| Renal Failure |
4.5% |
| Hypertension |
4.3% |
| Hyperparathyroidism |
4.0% |
| Anaemia |
2.2% |
| Hyperphosphataemia |
1.3% |
| Diabetes Mellitus |
1.2% |
| Vitamin Supplementation |
1.2% |
| Coronary Artery Disease |
1.0% |
| Prophylaxis |
0.6% |
| Pain |
0.6% |
| Cardiac Disorder |
0.6% |
| Anticoagulant Therapy |
0.5% |
| Renal Disorder |
0.5% |
| Hyperlipidaemia |
0.4% |
| Blood Cholesterol Increased |
0.4% |
| Atrial Fibrillation |
0.4% |
|
| Death |
54.1% |
| Myocardial Infarction |
4.6% |
| Cardiac Disorder |
4.1% |
| Sepsis |
3.4% |
| Vomiting |
3.2% |
| Unevaluable Event |
3.0% |
| Adverse Event |
2.7% |
| Cardiac Failure |
2.7% |
| Renal Transplant |
2.4% |
| Pyrexia |
2.3% |
| Cerebrovascular Accident |
2.0% |
| Pneumonia |
1.9% |
| Cardiac Arrest |
1.8% |
| Fatigue |
1.8% |
| Pruritus |
1.8% |
| Renal Failure Chronic |
1.7% |
| Diarrhoea |
1.7% |
| Renal Failure |
1.7% |
| Shunt Occlusion |
1.6% |
| Cardiovascular Disorder |
1.5% |
|
| Secondary |
| Product Used For Unknown Indication |
55.0% |
| Drug Use For Unknown Indication |
17.5% |
| Hyperparathyroidism Secondary |
6.8% |
| Hypertension |
3.4% |
| Renal Failure Chronic |
2.9% |
| Hyperparathyroidism |
2.3% |
| Dialysis |
1.5% |
| Diabetes Mellitus |
1.1% |
| Anaemia |
1.1% |
| Hyperphosphataemia |
1.1% |
| Arthralgia |
0.9% |
| Coronary Artery Disease |
0.8% |
| Arteriosclerosis Obliterans |
0.8% |
| Localised Infection |
0.8% |
| Procedural Hypotension |
0.8% |
| Hyperlipidaemia |
0.8% |
| Renal Failure |
0.8% |
| Renal Disorder |
0.6% |
| Muscle Spasms |
0.5% |
| Nephrogenic Anaemia |
0.5% |
|
| Arteriosclerosis Obliterans |
16.3% |
| Tooth Disorder |
9.6% |
| Hypercalcaemia |
6.4% |
| Vomiting |
6.1% |
| Pericardial Effusion |
5.8% |
| Shunt Occlusion |
4.7% |
| Cardiac Failure |
4.4% |
| Myocardial Infarction |
4.4% |
| Pneumonia |
4.4% |
| Shunt Thrombosis |
4.4% |
| Death |
4.1% |
| Unevaluable Event |
3.8% |
| Renal Failure |
3.5% |
| Sinus Tachycardia |
3.5% |
| Weight Decreased |
3.5% |
| Dysgeusia |
3.2% |
| Skin Ulcer |
3.2% |
| Syncope |
3.2% |
| Peripheral Arterial Occlusive Disease |
2.9% |
| Tonsillitis |
2.9% |
|
| Concomitant |
| Drug Use For Unknown Indication |
39.6% |
| Product Used For Unknown Indication |
23.0% |
| Nuclear Magnetic Resonance Imaging |
8.8% |
| Angiogram |
3.2% |
| Peritoneal Dialysis |
3.0% |
| Pain |
2.4% |
| Dialysis |
2.2% |
| Renal Failure Chronic |
2.1% |
| Hyperparathyroidism Secondary |
2.0% |
| Hypertension |
2.0% |
| Nuclear Magnetic Resonance Imaging Brain |
2.0% |
| Anaemia |
1.9% |
| Haemodialysis |
1.3% |
| Thrombosis Prophylaxis |
1.1% |
| Nuclear Magnetic Resonance Imaging Abdominal |
1.0% |
| Diabetes Mellitus |
1.0% |
| Prophylaxis |
1.0% |
| Imaging Procedure |
0.9% |
| Hyperphosphataemia |
0.9% |
| Multiple Myeloma |
0.7% |
|
| Vomiting |
24.1% |
| Skin Tightness |
11.6% |
| Therapeutic Response Decreased |
7.9% |
| Skin Induration |
5.2% |
| Death |
5.0% |
| Peritonitis Bacterial |
5.0% |
| Nephrogenic Systemic Fibrosis |
4.8% |
| Respiratory Failure |
3.9% |
| Nausea |
3.7% |
| Thirst |
3.3% |
| Thrombocytopenia |
3.1% |
| Tremor |
3.1% |
| Oedema Peripheral |
2.7% |
| Weight Decreased |
2.7% |
| Skin Ulcer |
2.5% |
| Hypotension |
2.3% |
| Renal Failure |
2.3% |
| Sepsis |
2.3% |
| Wheezing |
2.3% |
| Aplasia Pure Red Cell |
2.1% |
|
| Interacting |
| Product Used For Unknown Indication |
73.3% |
| Blood Parathyroid Hormone Increased |
6.7% |
| Metastases To Lung |
6.7% |
| Renal Cell Carcinoma |
6.7% |
| Renal Failure Chronic |
6.7% |
|
| Drug Interaction |
50.0% |
| Skin Lesion |
50.0% |
|
